Search | Clinical Trials Finder

Conditions: Sleep Disorders, Stress Disorders, Post-Traumatic
Interventions: Paroxetine, Prazosin, placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: Paroxetine hydrochloride 40 mg tablet, Paxil® 40 mg Table; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Stress Disorders, Post-Traumatic
Interventions: Cognitive-behavioral therapy and paroxetine-CR; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Durham, North Carolina + 1 more

Conditions: PTSD
Interventions: Placebo, Paroxetine, Positron Emission Tomography (PET) Imaging; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Anxiety Disorder
Interventions: Continued Paroxetine CR, Quetiapine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 72 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Depression
Interventions: desvenlafaxine SR, desipramine, paroxetine; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Healthy Adults
Interventions: SC Methylnaltrexone (MNTX), IV Methylnaltrexone (MNTX), Oral Paroxetine, SC Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Hypoactive Sexual Desire Disorder, Sexual Dysfunctions, Psychological
Interventions: Ginkgo Biloba, Sex Therapy (genital focus); Drug · Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Depressive Disorder, Major
Interventions: JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more

Conditions: Depression
Interventions: Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT); Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 79 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Posttraumatic Stress Disorder
Interventions: Paroxetine, Prolonged Exposure Therapy; Drug · Behavioral
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Postmenopausal Symptoms
Interventions: Brisdelle (paroxetine mesylate); Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 93
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more

Conditions: HIV Associated Neurocognitive Disorder
Interventions: Fluconazole, Paroxetine, Paroxetine and Fluconazole, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hot Flashes
Interventions: Brisdelle (paroxetine mesylate), Sugar pill; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 41 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Lake Worth, Florida • Naples, Florida • Greensboro, North Carolina + 6 more

Conditions: Depressive Disorder, Major
Interventions: saredutant (SR48968), paroxetine, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Alcoholism, Depression, PTSD
Interventions: paroxetine, desipramine, Naltrexone, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Social Anxiety Disorder, Anxiety Disorders
Interventions: paroxetine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 14
States / cities: Beverly Hills, California • Burbank, California • Jacksonville, Florida + 10 more

Conditions: Post Traumatic Stress Disorder
Interventions: clonazepam and paroxetine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Irritable Bowel Syndrome
Interventions: Paroxetine CR, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Depressive Symptoms
Interventions: paroxetine versus duloxetine; Drug
Lead sponsor: Duke University; Other
Eligibility: 20 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation, Substance-Related Disorders, Mild Cognitive Impairment, Quality of Life, Pain, Wounds and Injury, Brain Injuries, Chronic Disease
Interventions: Motivational Interviewing, Cognitive Behavioral Therapy Elements, Care Management, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Venlafaxine, Duloxetine, Mirtazapine, Diphenhydramine, Trazodone, Prazosin; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 24
States / cities: Scottsdale, Arizona • Beverly Hills, California • Sacramento, California + 20 more

Conditions: Social Anxiety Disorder, Social Phobia, Alcohol Use Disorder, Alcohol Abuse, Alcohol Dependence
Interventions: Paroxetine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Major Depressive Disorder
Interventions: EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo; Drug
Lead sponsor: Euthymics BioScience, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 43
States / cities: Arcadia, California • Beverly Hills, California • National City, California + 39 more

Search by objective public record fields.

Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees

Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg

Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy

Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder

Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression

Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder

Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

Naltrexone & SSRI in Alcoholics With Depression/PTSD

A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder

Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)

Comparing Paroxetine and Duloxetine on Cardiovascular Measures

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)